SCHEMBL1660094

SCHEMBL1660094

CCc1csc(Br)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12764496 0.81
SCHEMBL10062532 0.77 RAB9A (0.48)
SCHEMBL1230092 0.77
SCHEMBL11483559 0.76 CCR4 (0.46)
SCHEMBL285537 0.75
SCHEMBL3131400 0.75
SCHEMBL2256127 0.75
SCHEMBL91500 0.75
SCHEMBL21962502 0.75
SCHEMBL2894565 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062407-A1 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER UNIV WAKE FOREST HEALTH SCIENCES (US) 2026-03-05 US disclosed
US-20250381278-A1 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER UNIV WAKE FOREST HEALTH SCIENCES (US) 2025-12-18 US disclosed
EP-4577211-A2 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER Wake Forest University Health Sciences (US) 2025-07-02 EP disclosed
US-20250011316-A1 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER WAKE FOREST UNIVERSITY HEALTH SCIENCES 2025-01-09 US disclosed
WO-2024044744-A2 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) 2024-02-29 WO disclosed
US-11834449-B2 TYK2 inhibitors and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-12-05 US disclosed
US-11834449-B2 TYK2 inhibitors and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-12-05 US disclosed
US-20230242535-A1 IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION BRISTOL MYERS SQUIBB CO (US) 2023-08-03 US disclosed
US-20230219942-A1 COMPOUNDS COMPRISING A THREE RING CORE AS PD-1/PD-L1 BLOCKERS RELIVE THERAPEUTICS INC. (CA) 2023-07-13 US disclosed
US-11053241-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2021-07-06 US disclosed
CN-101050204-A Method for preparing compound of thiazole formaldehyde class JIUZHOU PHARMA CO LTD ZHEJIANG (CN) 2007-10-10 CN disclosed
US-7214801-B2 Condensation reagents and a process for their preparation LANXESS DEUTSCHLAND GMBH (DE) 2007-05-08 US disclosed
CN-1310893-C Condensation reagent and its preparation method BAYER AG (DE) 2007-04-18 CN disclosed
WO-2006130986-A1 AZACYCLOHEXANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE MERCK FROSST CANADA LTD. (CA) 2006-12-14 WO disclosed
US-7064216-B2 Condensation reagents and a process for their preparation BAYER AKTIENGESELLSCHAFT (DE) 2006-06-20 US disclosed
EP-1216997-B1 2-bromo/chloro-thiazolium salts and their use as condensation agents LANXESS DEUTSCHLAND GMBH (DE) 2006-02-15 EP disclosed
US-20050267174-A1 Condensation reagents and a process for their preparation RUDOLPH JOACHIM 2005-12-01 US disclosed
US-20020156287-A1 Condensation reagents and a process for their preparation LANXESS DEUTSCHLAND GMBH (DE) 2002-10-24 US disclosed
CN-1365975-A Condensation reagent and its preparation method BAYER AG (DE) 2002-08-28 CN disclosed
EP-1216997-A2 2-bromo/chloro-thiazolium salts and their use as condensation agents BAYER AG (DE) 2002-06-26 EP disclosed